——
EXCYTE LLC is committed to the R&D and industrialization of monoclonal antibody medicines, multi-functional antibody medicines and CAR-T/TCR-T cell immunotherapy.
EXCYTE antibody humanization technology is based on bioinformatics and small-scale expression combination library to generate humanized sequence combinations with the highest “human” homology.
There are two ways to optimize antibody affinity in EXCYTE: Single point complete randomization combined with hot spot combination pathway (PM) and segment complete block mutation (BM) pathway.
EXCYTE naive antibody phage display library is built by acquiring the PBMC of 25 healthy people from around the world. The donors include Chinese, Japanese, Filipino, Vietnamese, Cambodian, Latin American, Caucasian, Afro American, American Indian, German, Canadian, French, British, Russian, Mongolian etc.
Based on the latest clinical progress, the bispecific antibody platform of EXCYTE, which combins two unique monoclonal antibody into one, has been tested as a novel molecule to realize the activity effect of 1+1>2
Taking ScFv as the main form (which is like the "eye" of a CAR-T), the EXCYTE antibody library provides the tumor specific ScFv and core components for any CAR-T project.
——
EXCYTE offers antibody hits and leads isolation and screening services to any target of interest chosen by customer
——
EXCYTE LLC, an institution jointly founded by a number of international experts in the field of biomedicine, is committed to the R&D of multi-functional antibody drugs and CAR-T/TCR-T cell immunotherapy
——
EXCYTE LLC, an institution jointly founded by a number of international experts in the field of biomedicine, is committed to the R&D of multi-functional antibody drugs and CAR-T/TCR-T cell immunotherapy
M802 bispecific antibody binds to a tumor target and an immune target
August 31, 2017, Novartis announced that the United States FDA has app
